Orforglipron 36 mg lowered weight and blood sugar more than 12 mg

The new evidence covers three questions. A meta-analysis asked whether the higher 36 mg dose is meaningfully stronger than 12 mg. A Japanese late-stage trial asked how tolerable the drug is over a year in an East Asian population. The ACHIEVE-4 trial began the work of comparing heart safety against insulin glargine in adults who already have heart or kidney disease ¹.

Six randomized controlled trials, meaning studies where people were placed into dose groups by chance, were pooled. Together they included 3,459 adults with obesity ². The trials compared 12 mg and 36 mg daily doses of orforglipron. The higher dose produced larger average reductions in percentage body weight, absolute body weight, body mass index, a measure of weight relative to height, blood sugar, and waist circumference ². It also led to larger reductions in triglycerides, a type of fat in the blood, and systolic blood pressure, the top number in a blood pressure reading ². These differences met the usual standard for statistical significance, meaning they were unlikely to be chance findings ².

Adverse events were comparable between the two doses. The analysis did not find a meaningful difference in gastrointestinal side effects or pancreatic function. There was a small difference in pulse rate, but the authors did not consider it clinically significant ². The abstract also mentions planned subgroup analyses by diabetes status and treatment duration, but it does not include those results in the excerpt ².

ACHIEVE-J was a late-stage trial in 40 medical centers in Japan. It assigned 401 adults with type 2 diabetes to one of three daily doses: 3 mg, 12 mg, or 36 mg. The main question was safety over 52 weeks ¹. About 85% of participants had at least one treatment-emergent adverse event, which means any medical issue that appeared or worsened during the study. The rate was higher in the 36 mg group, 88%, than in the 3 mg group, 81%, or the 12 mg group, 84%. The abstract noted that most events were mild. Overall, 88% completed the treatment period ¹.

The trial was open-label, meaning participants and researchers knew which dose was being taken. That can influence how mild side effects are reported ¹. This was a safety-focused study; it was not designed to measure weight loss or blood sugar differences between doses.

ACHIEVE-4 is a phase 3 event-driven trial run across 317 sites in 16 countries. It enrolled adults with type 2 diabetes who had an HbA1c, a measure of average blood sugar over about three months, between 7.0% and 10.5%, a body mass index of 25 or more, and established cardiovascular or chronic kidney disease. Participants were randomly assigned to orforglipron up to 36 mg daily or insulin glargine once daily. The primary outcome was the time until one of four major heart events: cardiovascular death, nonfatal heart attack, nonfatal stroke, or hospitalization for unstable angina. These four events together are called MACE-4 ³.

The trial was designed to declare orforglipron non-inferior if the upper boundary of the 95% confidence interval for the hazard ratio was below 1.8. A hazard ratio compares the timing of events between the groups. A confidence interval is a range that likely contains the true effect. In plain terms, 1.8 is a wide safety margin ³. The published abstract describes the methods; it does not include the main heart-event result in the excerpt available ³.

These additions line up with what earlier trials and summaries reported. In the ATTAIN-2 trial, 36 mg of orforglipron produced an average weight loss about 7.1 percentage points greater than a dummy pill after 72 weeks in adults with obesity and type 2 diabetes ⁴. In the ACHIEVE-3 trial, 12 mg and 36 mg lowered HbA1c by 1.71% and 1.91%, respectively, at 52 weeks ⁵. The new pooled analysis supports the same pattern: the higher dose does more for body weight and blood sugar ².

Gastrointestinal side effects remain the main reason people stop treatment. In earlier work, 58 to 59% of people on 12 to 36 mg reported gastrointestinal issues, and about 6 to 10% stopped because of side effects ⁴. The Japanese study showed a similar overall side-effect burden, with the highest dose producing the most events, though most were mild ¹.

Orforglipron also improved several risk markers in earlier analyses. A study of cardiovascular risk biomarkers found reductions in systolic blood pressure, higher HDL cholesterol, lower triglycerides, and lower high-sensitivity C-reactive protein, a marker of inflammation ⁶. A pharmacokinetic study confirmed that the 36 mg capsule dose used in trials is bioequivalent to the 17.2 mg tablet strength, meaning the body absorbs the same amount of drug ⁷. An indirect comparison of oral semaglutide 25 mg and orforglipron 36 mg suggested that estimated weight loss with orforglipron may be less than with that higher oral semaglutide dose ⁸.

ACHIEVE-4's main heart-event result is not available in the abstract excerpt, so we cannot say whether orforglipron met its safety margin against insulin glargine ³. The Japanese study lasted one year; longer safety data in East Asian populations are still absent. The pooled dose comparison combined six trials of varying lengths, and its average results cannot predict how any one person will balance benefit and side effects ². The evidence does not establish that the higher dose is the right maintenance dose for everyone.